Venmax Drugs (531015)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 675% indicates strong recent demand traction, though from a tiny base.
• Piotroski F-Score of 7/9 suggests improving financial fundamentals.
• Positive ROCE of 5.29% shows capital employed is generating some operating return.
• Market cap of ₹2 Cr against latest quarterly sales of ₹2 Cr means the stock is priced for very little scale.
• Reported profit growth of 106% and PEG of 0.07 suggest cheap-looking growth if the numbers are clean.

Concerns

• ROE of -92.31% signals severe net losses and shareholder value destruction.
• Latest quarter net profit is ₹0 Cr, so the P/E of 25.63 is not backed by meaningful earnings.
• Current price of ₹4.18 is outside the reported 52-week range of ₹19.01 - ₹36.96, indicating data inconsistency or serious market de-rating.
• No book value, debt/equity, or promoter holding data, plus 0% dividend yield, makes transparency and returns to shareholders poor.
• Tiny market cap of ₹2 Cr creates liquidity and manipulation risk for retail investors.

AI Analysis

Let me begin with a simple truth: when I look at Venmax Drugs, I see a very small, very volatile pharmaceutical name, not a compounder. Market cap is just ₹2 Cr, and even against the latest quarter's sales of ₹2 Cr, the market is pricing negligible scale. Sales growth of 675% catches my eye, but I must be careful. A 675% growth rate from a microscopic base is not the same as a durable franchise. The ROE is minus 92.31%. That destroys shareholder equity. A business that earns negative returns on equity cannot be valued as a quality franchise. ROCE of 5.29% is only a small consolation, and the latest quarter's net profit is ₹0 Cr—no real earnings. This is a turnaround candidate, not a stalwart. Graham would demand a margin of safety. At a P/E of 25.63, there is no earnings-based margin. The PEG of 0.07 makes the growth look cheap, but I never trust a low PEG when the earnings quality is weak. Profit growth of 106% is reported, but from what base? A company with minus 92% ROE should not be bought on percentage growth alone. The Piotroski F-score of 7/9 does suggest operational improvement, which I respect. But improvement from a very weak base is not business quality. There is no dividend, no book value, no promoter holding data, and the 52-week range is inconsistent with the current price. Those are warning signs of incomplete information or real problems. In short, this is a speculation, not an investment. I need proven profitability, a moat, and transparency. Venmax has none of those today. I will watch from the sidelines.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer